Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BXT4
UPID:
TDRD1_HUMAN
Alternative names:
Cancer/testis antigen 41.1
Alternative UPACC:
Q9BXT4; A6NEN3; A6NMN2; B3KVI4; B4E2L5; D3DRC2; Q4G0Y8; Q6P518; Q9H7B3
Background:
Tudor domain-containing protein 1, also known as Cancer/testis antigen 41.1, is pivotal in spermatogenesis. It represses transposable elements, preserving germline integrity through the piRNA metabolic process. This process involves piRNA and Piwi protein complexes, crucial for transposon methylation and repression. Additionally, it ensures Piwi protein localization to the meiotic nuage and regulates the piRNA pathway, facilitating the recruitment of biogenesis factors for proper transcript and piRNA entry into Piwi proteins.
Therapeutic significance:
Understanding the role of Tudor domain-containing protein 1 could open doors to potential therapeutic strategies.